BusinessCanadaPress release

Avicanna Reports Q2 2026 Financial Results

Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product salesQUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and […]

Financial Post1 hr ago

Published by CurrentWire Aug 14, 2026 at 6:35 PM ET · First coverage Aug 14, 2026 at 6:31 PM ET

Compiled by CurrentWire News Desk

Summary based on reporting from Financial Post.

Read the full report at Financial Post

X Facebook LinkedIn Email

In this story

Automated coverage analysis

Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.

Source mix

1 press release

Coverage

1 publication is covering this story.

Financial PostTier B
Avicanna Reports Q2 2026 Financial Results(opens original report in a new tab)1 hr ago

CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.